Abstract:Importance Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension (PH), characterized by pulmonary arterial remodeling. The prevalence of PAH is approximately 10.6 cases per 1 million adults in the US. Untreated, PAH progresses to right heart failure and death. Observations Pulmonary hypertension is defined by a mean pulmonary artery pressure greater than 20 mm Hg and is classified into 5 clinical groups based on etiology, pathophysiology, and treatment. Pulmonary arterial hypertension is 1 of the 5 groups of PH and is hemodynamically defined by right heart catheterization demonstrating a mean pulmonary artery pressure greater than 20 mm Hg, a pulmonary artery wedge pressure of 15 mm Hg or lower, and a pulmonary vascular resistance of 3 Wood units or greater. Pulmonary arterial hypertension is further divided into subgroups based on underlying etiology, consisting of idiopathic PAH, heritable PAH, drug- and toxin-associated PAH, pulmonary veno-occlusive disease, PAH in long-term responders to calcium channel blockers, and persistent PH of the newborn, as well as PAH associated with other medical conditions including connective tissue disease, HIV, and congenital heart disease. Early presenting symptoms are nonspecific and typically consist of dyspnea on exertion and fatigue. Currently approved therapy for PAH consists of drugs that enhance the nitric oxide-cyclic guanosine monophosphate biological pathway (sildenafil, tadalafil, or riociguat), prostacyclin pathway agonists (epoprostenol or treprostinil), and endothelin pathway antagonists (bosentan and ambrisentan). With these PAH-specific therapies, 5-year survival has improved from 34% in 1991 to more than 60% in 2015. Current treatment consists of combination drug therapy that targets more than 1 biological pathway, such as the nitric oxide-cyclic guanosine monophosphate and endothelin pathways (eg, ambrisentan and tadalafil), and has shown demonstrable improvement in morbidity and mortality compared with the previous conventional single-pathway targeted monotherapy. Conclusions and Relevance Pulmonary arterial hypertension affects an estimated 10.6 per 1 million adults in the US and, without treatment, typically progresses to right heart failure and death. First-line therapy with drug combinations that target multiple biological pathways are associated with improved survival.

Renal replacement therapy as a therapeutic option for right heart failure in severe pulmonary arterial hypertension

Cardiorenal Syndrome in Right Heart Failure Due to Pulmonary Arterial Hypertension—The Right Ventricle as a Therapeutic Target to Improve Renal Function

Management of hepatorenal syndrome in liver cirrhosis: a recent update

Intensive care, right ventricular support and lung transplantation in patients with pulmonary hypertension

Effectiveness and Safety of Peritoneal Dialysis Treatment in Patients with Refractory Congestive Heart Failure Due to Chronic Cardiorenal Syndrome.

Medical Management of Right Ventricular Dysfunction in Pulmonary Arterial Hypertension

Heart Rate Reduction Improves Right Ventricular Function and Fibrosis in Pulmonary Hypertension

A Retrospective Study of Continuous Renal Replacement Therapy Versus Intermittent Hemodialysis in Severe Acute Renal Failure

Acute decompensated pulmonary hypertension

Management of Acutely Decompensated Pulmonary Hypertension

Atrial flow regulators for the treatment of pulmonary arterial hypertension: what does the future hold?

Recent Advances in the Treatment of Pulmonary Arterial Hypertension

Successful treatment of severe renal failure caused by malignant hypertension using a combination of renin-angiotensin-aldosterone system inhibitors: a case report

A review regarding the article `Right heart catheterization in idiopathic pulmonary hypertension: An all-inclusive necessity'

Kidney Replacement Therapies in Advanced Heart Failure – Timing, Modalities, and Clinical Considerations

Renal Denervation in Management of Heart Failure with Reduced Ejection Fraction: A Systematic Review and Meta-Analysis

Recovery from kidney failure associated with chronic thromboembolic pulmonary hypertension following pulmonary thomboendarterectomy

Risk stratification and medical therapy of pulmonary arterial hypertension

Early implementation of renal replacement therapy after lung transplantation does not impair long-term kidney function in patients with idiopathic pulmonary arterial hypertension

Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.

Mechanisms and treatment of pulmonary arterial hypertension